Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma (NHL)
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM)

Interventions: Drug: VOB560
Drug: MIK665

First Posted Date: 2021-01-08

Last Posted Date: 2024-07-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT04702425

Locations: 🇺🇸
Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr, Houston, Texas, United States
🇪🇸
Novartis Investigative Site, Santander, Cantabria, Spain

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Phase 1

Active, not recruiting

Conditions: KRAS G12C Mutant Solid Tumors
Carcinoma, Non-Small-Cell Lung
Carcinoma, Colorectal
Cancer of Lung
Cancer of the Lung
Neoplasms, Lung
Neoplasms, Pulmonary
Lung Cancer
Pulmonary Neoplasms
Pulmonary Cancer

Interventions: Drug: JDQ443
Drug: TNO155
Biological: tislelizumab

First Posted Date: 2021-01-07

Last Posted Date: 2024-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 344

Registration Number: NCT04699188

Locations: 🇺🇸
Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Providence Cancer Center, Portland, Oregon, United States

and more 3 locations

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

Phase 3

Withdrawn

Conditions: Age-related Macular Degeneration (AMD)

Interventions: Drug: brolucizumab

First Posted Date: 2021-01-06

Last Posted Date: 2021-09-23

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04697953

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: 177Lu-PSMA-617
Drug: 68Ga-PSMA-11
Drug: ARDT
Other: Best supportive care

First Posted Date: 2020-12-30

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 470

Registration Number: NCT04689828

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸
Univ of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Tulane Uni Health Sciences Center, New Orleans, Louisiana, United States

and more 18 locations

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Phase 4

Completed

Conditions: Age-related Macular Degeneration

Interventions: Biological: Brolucizumab

First Posted Date: 2020-12-22

Last Posted Date: 2024-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT04679935

Locations: 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

Completed

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: Ocrelizumab
Drug: Ofatumumab

First Posted Date: 2020-12-21

Last Posted Date: 2022-10-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT04676555

Locations: 🇦🇺
Novartis Investigative Site, Parkville, Victoria, Australia

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Capmatinib

First Posted Date: 2020-12-21

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT04677595

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Phase 2

Recruiting

Conditions: Severe Malaria

Interventions: Drug: KAE609
Drug: IV Artesunate
Drug: Coartem

First Posted Date: 2020-12-19

Last Posted Date: 2024-12-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 252

Registration Number: NCT04675931

Locations: 🇺🇬
Novartis Investigative Site, Tororo, Uganda

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Phase 4

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Drug: Fingolimod 0.5mg

First Posted Date: 2020-12-16

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT04667949

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Recruiting

Conditions: Melanoma

Interventions: Drug: dabrafenib
Drug: trametinib

First Posted Date: 2020-12-14

Last Posted Date: 2024-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT04666272

Locations: 🇨🇳
Novartis Investigative Site, Wuhan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy